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Abstract 
The high burden of infectious diseases and the growing problem of noncommunicable and 
metabolic disease syndromes in South Africa (SA) forces a more focused research approach 
to facilitate cutting-edge scientific growth and public health development. Increased SA 
research on these diseases and syndromes and the collection of associated biospecimens 
has ensured a plethora of biobanks created by individuals, albeit without the foresight of 
prospective and collective use by other local and international researchers. As the need for 
access to high-quality specimens in statistically relevant numbers has increased, so has the 
necessity for the development of national human biobanks in SA and across the 
Continent. The prospects of achieving sustainable centralized biobanks are still an emerging 
and evolving concept, primarily and recently driven by the launch of the H3Africa 
consortium, which includes the development of harmonized and standardized biobanking 
operating procedures. This process is hindered by a myriad of complex societal 
considerations and ethico-legal challenges. Efforts to consolidate and standardize 
biological sample collections are further compromised by the lack of full appreciation by 
national stakeholders of the biological value inherent in these collections, and the 
availability of high quality human samples with well-annotated data for future scientific 
research and development. Inadequate or nonexistent legislative structures that 
specifically regulate the storage, use, dispersal, and disposal of human biological samples 
are common phenomena and pose further challenges. Furthermore, concerns relating to 
consent for unspecific future uses, as well as access to information and data protection, are 
all new paradigms that require further consideration and public engagement. This article 
reviews important fundamental issues such as governance, ethics, infrastructure, and 
bioinformatics that are important foundational prerequisites for the establishment and 
evolution of successful human biobanking in South Africa. 
 
Introduction 
South Africa (SA), with a population of 60 million inhabitants, has one of the 
highest burdens of infectious disease, predominantly driven by the syndemic of human 
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immunodeficiency virus (HIV) and tuberculosis (TB) and a growing problem of 
noncommunicable and metabolic disease syndromes. This creates a highly vulnerable and 
susceptible population that requires a focused research and development agenda to find 
indigenous solutions through1,2 national, continental, and international collaborations. 
 
Over the last 2 decades, biobanking has emerged as a complex science bringing together 
multiple biological, social science, and legislative disciplines in order to provide the basis 
and platform for the generation of science-based economies in an era of rapidly emerging 
genomic and proteomic epidemiological-based discoveries. Biobanking of high quality and 
well-annotated biospecimens provides an essential resource that would facilitate cutting-edge 
scientific research and public health development.3 
 
Biological specimen repositories in SA are generated for a number of reasons and 
incentivized by a variety of stake-holders that are typically academic, government, and 
commercially driven, as is typically seen in more advanced science based economies.4 
Despite the scourges of HIV, TB, and now metabolic syndromes,5,6 patient-driven 
advocacy groups supporting the collection of biological samples to accelerate discovery 
have not yet emerged as a powerful force on the landscape of South African biological 
research, as one has seen in more affluent global communities.7 Typically, biobanks in SA 
are concerned with the storage of human, animal, and plant biodiversity biological 
specimens. However, for the purpose of this review, we will focus specifically on human 
biobanking. 
 
We are aware that there are a number of biobanks operating on a smaller scale in SA, 
however limited information is available. These range from smaller collections associated 
with research projects within academic institutions, to large collections and well-archived 
diagnostic samples that are housed in the pathology departments within the numerous 
mega teaching hospitals in SA. More formal government-based blood, forensic, and plant 
biodiversity banks also exist while private nonprofit registries and private profit-based cord 
and stem cell banks, and those associated with clinical trials, are increasingly emerging. 
Table 1 lists examples of existing human biobanks in SA. However, little evidence is 
available on whether some of them are fully compliant with quality standards and conduct 
procedures in accordance with international and national biobanking best practices and 
guidelines such as those published by ISBER and NCI.8,9 Despite a plethora and diversity of 
biobanks, the establishment of a national harmonized biobank in SA is still an emerging 
concept.10 This has recently been accelerated by the launching of the H3Africa consortium,11 
whose mission is to accelerate the science of genomic research on the continent in the wake of 
the successful human genome project.11 Inherent in this initiative is the formal 
establishment of strategically located  biobanks  across  Africa  and  the  formation  of  a 
bioinformatics network that will not only assist the biobanks with informatics capacity, but 
also primarily support the projects with the generation of quality assurance and storage of a 
huge amount of genomic data that will emerge from the funded projects. Two of the four 
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proposed central biobanks that have been funded by the H3Africa project are located in SA 
and are anticipated to ramp up over a 2-year period into fully operational biobanks capable of 
receiving up to 100,000 samples a year from projects in SA and across the continent. 
Achieving these targets is hampered by myriad complex considerations  associated  with  
the  concept  of  long-term storage of biological samples, namely ethical, legal, political, 
societal, religious, cultural, financial, and educational challenges not previously examined 
or debated to any great depth in Africa before. Thus, for the purpose of this article, we will 
focus on fundamental issues such as governance, ethics, infrastructure, and bioinformatics 
that are important foundational prerequisites that require deep consideration by any 
community considering the establishment of successful human biobanking. Of the two 
biobanks funded in SA, one principal investigator has opted to go the route of establishing 
from scratch a greenfields H3Africa biobank, while the other has opted to adapt an 
existing drug trial biobanking facility to the needs of the H3Africa projects and 
harmonization processes. 
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Governance 
Typically, governance of biobanks globally is dictated by external and internal structures 
that ensure there is compliance with rapidly evolving principles of both global and 
indigenous standards of ethics and social justice. SA is subject to the same external 
governance structures ascribed to by the World Health Organisation (WHO) and the 
Helsinki Declaration. The Africa Union legislative structures have not as yet specifically 
addressed the concept of biological preservation of the continent’s huge biodiversity 
repertoire or promoted the legislative instruments to encourage awareness of biological value 
and data protection directives to guide research and development in this arena. However 
there are instruments such as the Abuja declaration of 200112 and the Africa Health 
Strategy 2007 to 201513 that allude to the burden of human disease and the prerequisite that 
should be put in place for Africa as a whole to emerge as a science-driven economy capable 
of addressing its own health burdens through research and development. Embedded in these 
policies are the opportunities that prescribe to the formulation of legislative guiding principles 
that will create the opportunity for biological preservation and scientific discovery. 
 
The SA Department of Science and Technology (DST), through various subprograms and 
public entities, is committed to supporting the generation of a strategic knowledge and 
scientific discovery-based economy, through sustainable utilization of its biodiversity, 
promoting value and indigenous knowledge systems secured by intellectual property 
management policies as outlined in its 2011/2012 annual report.14 
 
The DST has clearly articulated that underpinning many of these programs is the need to 
have oversight over the formalization of central biobanks that will serve the function of 
keeping well-preserved specimens and data as national assets for the purpose of added 
value and for posterity, thereby creating the opportunity for accelerating indigenous 
discovery in an environment that is regulated and protected against biopiracy. This concept 
is generally understood as the act of gaining access to biological materials such as genetic 
material or cell lines from which some academic or commercial benefit may be derived by 
a technologically advanced country or organization without the intention of fair 
compensation to the peoples or nations from whose territory the materials originated. It 
refers to a process through which researchers representing governments, universities, or 
research institutions traverse the globe establishing networks with the specific aim of 
obtaining biological and genetic material that are deemed to have intellectual or commercial 
value within the historical context of dispossession.15 An example of this was well 
articulated by a benefit audit of a research project recently conducted in Cameroon, which 
showed very little acknowledgment of the investigators involved with gathering the 
material in the form of names on publications as an example.16 Wonkam et al. refer to this 
as a ‘‘biotechnological gold rush’’.16 
 
The responsibility for human biobanking by definition lies within  the purview  of the South  
African  Department  of Health (DOH) and the National Health Laboratory Services (NHLS) 
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that is responsible for the training and performance of all public diagnostic services across 
SA. The NHLS is a public health laboratory service with a network of laboratories across 
SA. It was established in 2001 by an Act of Parliament to provide diagnostic pathology 
laboratory services to the national and provincial health departments. Its activities comprise 
diagnostic laboratory services, research, teaching, and training.  The core function of  
NHLS is to support the mandate of the DOH and is the largest diagnostic pathology 
laboratory service in SA. The NHLS employs 6700 staff over 349 laboratories across nine 
provinces in SA and serves 80% of the South African population. A major mandate of the 
NHLS is the training of pathologists and medical technologists in conjunction with the nine 
university medical schools and universities of technology across SA. NHLS scientists conduct 
research specific to South African health issues, such as tuberculosis, meningitis, malaria, 
pneumonia, HIV/AIDS, and cancer. These researchers make major contributions to national 
and international medical literature and form a huge archive of hospital-based biological 
specimens. The NHLS already houses and supports central biobanks, such as the National 
Institute for Occupational Health (NIOH) biobank located in Johannesburg, and the recently 
funded H3Africa NHLS Stellenbosch University biobank based in Tygerberg Hospital in Cape 
Town. What is not clear is how the strategic visions of the DST, DOH, and the NHLS for 
harnessing the biological value inherent in our communities will form synergies with the 
externally funded initiatives such as the H3Africa towards the creation of centralized 
biobanks. Formal discussions are currently underway by the major stakeholders and the 
external funding agencies, to chart a common agenda to synchronize oversight, 
governance, and access to scarce financial resources. 
 
Legal and Ethical Considerations 
In SA, all matters relating to the use of blood and blood products, cell-based therapy, tissue 
transplants, information derived from genetic research, biological tissue banking, use, and 
dispersal and disposal of human biological samples are governed by the National Health Act 
(NHA), Act No 61 of 2003,17 which superseded and replaced the Human Tissue Act No 65 
of 1983.18 Specifically, the legal aspects of using human biological material are governed 
by Chapter 8 and ethics guidelines are governed by Chapter 9 of the NHA. Other bodies 
that are involved in the ethics surrounding research are the Health Professionals Council of 
South Africa (HPCSA) and the South African Medical Research Council. The South African 
Intellectual property Rights from Publicly Financed Research and Developmental Act (IPR 
Act) regulates intellectual property rights, patents, and benefits applicable from human 
biological material.19 
 
Although the NHA in Chapters 8 and 9 addresses research surrounding biological material 
and the ethics involved, it has failed to keep abreast of a rapidly changing paradigm in 
science and the complex interrelationship between science, the law, and social justice. The 
NHA was approved in 2004 by the president of SA; however Chapter 8 was not enacted at 
that stage as it was believed to require significant revision. Since then, several sections of 
Chapter 8 were revised and it was enacted on 1 March 2012.20 Despite these revisions, there 
are still many discrepancies and shortcomings in Chapter 8 of the NHA. However, it will only 
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be revised with the entire act, which is pending.21 Many aspects of the current NHA as it 
relates to biobanking and the use of cell-based therapies are ambiguous and require further 
clarity and precise definitions to avoid misinterpretation by the law. For instance, there is 
legislation regarding tissue banking and transplantation in the NHA; however biobanking 
per se is not directly addressed. The NHA does not comment on national policies surrounding 
biobanking in South Africa. Questions that still need to be addressed are governance and 
policies that will be required for the existence of national biobanks. Other areas of ambiguity 
are definitions of various terms as suggested by Pepper et al.21 The definition of ‘stem cells’ as 
‘cells that have both the capacity to self-regenerate as well as to differentiate into mature 
specialized cells’ is consistent in three of the regulations published on 2 March 2012; 
however a cell has been given different definitions in other regulations published on the 
same day.22 This kind of discrepancy will not hold up well in a court of law and definitely 
requires urgent revision of the act. 
 
All health-related research in terms of the Health Act No 61.2003 must be approved by an 
accredited research ethics committee. All health-related biomedical and social research at 
any of the academic institutions in SA requires ethical clearance by an accredited Health 
Research Ethics Committee (HREC) before the research commences. HREC are registered 
with the South African Department of Health’s National Health Research Ethics Council 
(NHREC) and with the academic Office for Human Research Protection. 
 
The need for informed consent is considered an ethical hallmark of all research on human 
subjects and is enshrined in many international guidelines such as the Declaration of 
Helsinki23 and Council for International Organizations of Medical Sciences Guidelines 
(CIOMS).24 It requires that all participants be informed of any risks inherent in the research, 
and these risks must be voluntarily accepted,25 and is based on the principle that all 
individuals have the right to decide what is done with  their body.26 The difficulty  with 
biobanking research is that the future uses of research may not be known  at the  time of  the 
collection of the biological samples and thus if any future research proposes to use the 
samples beyond that detailed in the consent form, all participants must be contacted and 
their reconsent obtained. Due to the onerous task that this presents, alternative forms of 
consent have been proposed. 
 
Broad consent occurs where the participants’ consent to the use of their sample for 
unspecified future uses. As the participant is not informed about the research at the time of 
donation, they cannot be aware of the risks or benefits of the research and their consent is 
not truly informed as required by the Declaration of Helsinki. It would appear that, in order 
to comply with the Declaration, each participant must be recontacted to reobtain their 
consent. However, S. 25 of the Declaration does state that there are situations in which it 
may not be possible and REC approval will suffice. Due to the potential social value of 
biobanking and the fact that the use of the sample contains little risk for the participant, it has 
been suggested that for biobanking, we need to move away from the ‘‘one study/one 
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informed consent’’ paradigm,27 and recontacting the participant is not necessary. 
Furthermore, the broad consent model is preferable as it has the advantage of simplifying 
the consent process and has even received the support of the WHO.28 
 
Another option is tiered consent  whereby participants select from a range of options in the 
consent document: they can opt for broad consent, opt to be recontacted prior to 
secondary use of their samples, opt for an REC to consent on their behalf,29 or they can 
consent to certain disease-specific research.30 Such a model does not completely eradicate 
the need for reconsent, as there may be an option for reconsent in certain circumstances. 
However, it does reduce the need for recontact and reconsent and it also presents the 
participant with a range of consent options, thus striking a balance between progress and 
science and respecting the autonomy of participants.31 The South African NHA 2003 does 
not consider the issue of secondary uses of samples and simply states that prior to the use 
of a biological sample, informed consent must be obtained. The Ethics in Health Research 
Guidelines does state that each research institution should draft guidelines as to when 
reconsent is required and when a waiver of consent may be obtained,32 however this raises 
the possibility that there will be differing ethical guidelines as to consent across research 
institutions. 
 
The main risks with biobanking are those posed by unauthorized access to information, a 
matter of confidentiality and exploitation.33 Indeed, under the WHO guidelines, broad 
consent is only possible where samples are anonymized. Access to data must be limited to 
ensure that certain third parties cannot access the information, and genetic results must be 
kept confidential to ensure that there is no risk of stigmatization or discrimination. To 
ensure confidentiality, samples can be anonymized whereby all data identifying the individual 
are removed34 or the samples can be single or double coded and the sample can only then be 
identified by breaking the unique code.35 While the anonymization of data is ‘‘legally and 
ethically expedient’’ as it ensures that the sample cannot be re-identified,36 the difficulty 
is that this limits the usefulness of the sample33 and the participant cannot withdraw 
their sample.37 Thus, the CIOMS guidelines acknowledge that there are instances in which a 
sample may not be anonymized but coded and this enables the reconsent of participants as 
well as enabling them to withdraw their consent in the future. Neither the NHA 2003 nor 
the National Guidelines address these issues. They state that genetic material must be kept 
confidential but are silent as to whether samples can be anonymized or coded. 
 
Infrastructure 
To ensure proper preservation and protection of valuable biospecimens, it is essential to 
have a well-developed and reliable infrastructure that adheres to international guidelines 
and best practices. Key infrastructural issues relating to biobanking operations include the 
availability of constant power, efficient transport logistics, the availability of liquid nitrogen 
and dry ice, as well as the location of the biobank in terms of climate conditions. According 
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to the United Nations, SA is classified as a middle-income country38 with a well-
developed energy and transport sector and therefore has the capacity and potential to 
provide support for large-scale biorepository development and maintenance. 
 
Eskom is SA’s main electricity supplier, providing 95% of the country’s electricity 
requirements.39 The National Energy Regulator of South Africa (NERSA) is responsible 
for licensing the distribution of electricity to different regions in SA, and under the NERSA 
license the standard of services provided  must  meet  the  requirements  as  set  out  in  the 
Electricity Regulation Act.40 Since 2007, South Africa has faced electricity supply 
challenges that are mainly due to increasing consumer demand, aging infrastructure, and 
limited coal supplies. Providing secure energy has therefore become a priority of the SA 
government, with capacity-building plans including investments in renewable electricity 
generation systems that could be used to complement the existing supply systems.41 Due 
to possible short-term electricity shortages, backup generators and energy storage devices 
are important for ensuring a stable power supply for biorepository operations. Liquid 
nitrogen (LN2) is also readily available in most areas in SA, with companies such as Air 
Products South Africa (Pty) and African Oxygen Limited (Afrox) being two of the main 
providers. Long-term storage of samples in LN2 storage tanks could therefore serve as a 
more reliable alternative to storage in - 80°C freezers. 
 
SA has a modern transport infrastructure with an extensive network of road, rail, and air 
transport systems that would support collection and distribution of samples to and from a 
centrally located biorepository. A well-developed road infrastructure would support 
collection of biospecimens from more remote locations, while air links connect major cities 
in a hub and spoke-like distribution, allowing speedy transport between major depots. South 
African Airways (SAA) is the national carrier and has regular flights between SA’s 10 airports. 
SAA is the largest air carrier in Africa and in 2012 was voted the best airline in Africa for the 
10th year running by Skytrax.42 Courier companies such as World Courier, Marken, and 
DHL specialize in transporting biological samples according to IATA regulations and offer 
a strong SA and African hub network with advanced data freight management services. 
Despite the fact that SAA has an extensive route network operating to 28 cities on the 
continent, transport of biological samples between SA and other African countries is still a 
challenge, with poor infrastructure and prohibitive transport costs being the main 
problems.43 External operating environments within Africa can negatively impact the 
reliability of these services and compromise transport efficiencies of the operators. 
Innovative approaches to biospecimen collection and transport may be necessary to ensure 
faster and more cost-effective transport to and from biorepositories in SA and beyond into 
Africa as a whole. 
 
Unlike many other infrastructure sectors in SA, the telecommunications sector is 
dominated by the private sector. Due largely to the recent increase in the use of mobile 
phones and broadband networks in the country, telecommunications has become one of the 
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fastest growing economic sectors in SA.44 Recent increases in the number of undersea data 
cables connecting SA to the rest of the world have also led to improved internet access and 
speed. Until recently, Telkom has been the only fixed-line provider in the country and has 
developed an extensive network over a number of decades.41 However, the demand for 
faster broadband has meant an increase in the use of wireless broadband which, although 
faster, is not as reliable as the fixed-line service. The replacement of current ADSL lines 
with fiberoptic cables will see a 10-fold improvement in speed, up to 100 Megabits per 
second (Mbps). However, these replacements will take a number of years, meaning that 
Telkom’s monopoly on the fixed-line industry will continue to affect competitiveness in the 
telecommunication industry. 
 
The Biorepository Laboratory Information 
Management System (LIMS) 
The successful implementation of a LIMS in a biobank assumes good laboratory practices 
that include the use of Standardized Operating Procedures (SOP) and standardized 
nomenclature.45 However, biobanks evolve as biospecimen collections expand. Very 
often, these specimen collections do not adopt a standardized labeling system or  an  
electronic  tracking  system,  with  the  result  that sample collections reside in freezers 
and/or laboratory corridors in a disorganized manner and are usually not subject to 
internationally-recognized quality management systems.  These  ad  hoc  repositories  
capture  a  wealth  of genetic  material  but  cannot  be  used  by  the  scientific community 
in general because of the lack of a query interface that easily captures the underlying 
sample history and phenotypes. The wealth of genetic material in SA has ensured that 
there is a plethora of biobanks, albeit biobanks that were created by individuals without 
the foresight of prospective use by other researchers. Therefore, an opportunity exists in 
SA for a coordinated effort aimed at developing SOPs at the level of collection, 
processing, management, and storage of samples and associated data. 
 
In resource-limited settings, it is helpful to assess both open-source (OS) and 
commercial-off-the-shelf (COTS) LIMS products as alternative options to facilitate SOPs 
implementation. Factors to consider include cost, flexibility, ease of implementation, as 
well as customization and security. The cost of COTS software includes the initial cost of 
acquiring the system, as well as the cost of maintenance and support throughout the 
software’s life cycle (i.e., licensing fees).46 OS software are usually available free of 
charge, however costs are incurred when customizing the software according to a 
biorepository’s needs, as well as managing and maintaining the system. While there are 
many OS LIMS systems, none of these can claim to manage the needs of a biobank (i.e., 
customized modules to track the biospecimen from the time of sample collection, to 
shipping, to sample preparation and analysis). For example, software such as CaTissue 
provides a Java-based application to handle sample storage but does not manage kit 
collection and shipping.47 BIKA LIMS,48 on the other hand, has been developed for 
sample processing in a laboratory but does not have any modules for kit collection, 
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shipping, and tracking chain-of-custody. While both CaTissue and BIKA lack specific 
functionality with regards to biospecimen handling, both these applications are open 
source and allow for community-based customization. The time taken, and cost of, 
customizing these OS LIMS have to be weighed against the cost of a biobank-ready 
LIMS product. Our observations to date suggest that COTS LIMS have a layer of 
customization that must be fit for specific laboratory needs. 
 
The harmonization of information as it pertains to sample collection, labeling, preparation, 
and storage facilitated by a biobank-accredited LIMS will ensure interoperability among 
biobanks both within SA and internationally. Furthermore, adopting a data standard within 
a biobank will facilitate the integration of research data with the biospecimens, as has been   
achieved   with   a   federated   database   model   implemented by the Karolinska Biobank. 
 
Sustainability 
In the continuing volatile global economic environment, with slow recovery, and some 
countries affected worse than others, creative strategies from team leaders are required to 
develop sustainability. Strategies in public biobanking operations on the continent are 
particularly vulnerable to long- term financial and other sustainability issues. 
 
Sustainable development is about enhancing human wellbeing and quality of life for all time, 
in particular those most affected by poverty and inequality. Each generation has to use 
resources efficiently in all endeavors and create new cross-generational infrastructure that 
addresses inefficiencies in health delivery, disease monitoring, and deliver new cost-effective 
solutions to diseases both current and those that will affect the future of the people, our 
planet, and prosperity.49 
 
Biobanking in Africa is one such essential newly emerging asset that needs expansion in SA. 
Public biobanks rely on multitudes of external support, primarily institutional and 
governmental. This financial and resource need creates a dependency in their conception 
phase. Particularly in SA, funding is primarily from the United States government-funded 
structures such as the National Institutes of Health (NIH) and other similar agents. The 
Wellcome Trust in the United Kingdom is also a strong supporter of biobank development 
in Africa. Further limited financial resources mean that networks, while being 
collaborative, are at another level competing for the same external resources in a bid to 
reach self-sustainability from initial funders. Funding is both time restricted and usage 
restrictive. Another aspect is that business planning and operations management first 
commence meeting funders’ requirements and are ‘‘project driven’’.50 
 
Thus, to attain sustainability, large central academic biorepositories need to switch to 
‘‘central general’’ biobanking of specimens and develop a ‘‘paying customer base’’ through 
considerations of revenue generation and diversification of services to develop a business 
model. In SA, developing public benefi biobanks that incorporate all aspects of business 
planning requires attention to the initial architecture of the project and incorporating 
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SMART modeling along the entire value chain. SMART modeling refers to a well-
formulated set of objectives under the headings of Simple, Measurable, Achievable, 
Realistic, and Time Bound.51 It is a benchmarking framework tool that can be used to 
test the value chain along its stages. The outcome should be that each process and stage is 
mutually exclusive and comprehensively exhaustive. Any business plan should take 
cognizance of on-going skills development and training as well as creating jobs. Within the 
community that the biobank operates, the value chain should incorporate small business or 
enterprise development, a key focus of the SA government.52 Various government funding 
programs are available to support tangible projects that are incorporated within the 
business model. Companies are allowed to contribute 1% of their net profi after tax 
towards such projects. Thus, the concept of Public Private Partnerships (PPPs) becomes 
critical to sustainability and accessing funds. Long-term projects such as biobanks 
require a continuous source of funding, particularly in the early start-up stage. Reliance 
on one stream or solely government sourced funding may lead to lack of ability to grow 
the project or attract private investors, particularly as government funding is seen as an 
interim initiative at most to create awareness and confidence in the project. Such 
partnerships, once structured, enable projects to leverage and access funds allocated by 
government towards Enterprise Development. This year there is a surplus of ZAR 21 
billion available for such funding.53 These programs are not clearly understood or 
implemented; hence large pools of funds lie unused each financial year.52 
 
Another aspect of sustainability is costing planning and data systems together with clear 
governance and strong ethics management policies. Excellent data systems and data 
gathering that meet a client’s requirements will result in return business and attract interest 
in the biobank. 
 
In summary, any combination of business models, while for the public benefit, has to 
incorporate nominal and marked up prices for services, data, consulting, processing, 
storage, logistics, and procurement management (unpublished data). Central biobanks 
can also consider offering management services to smaller biobanks, thereby consolidating 
operations and creating expansion through this mechanism. 
 
Conclusion 
The concept of centralization of biological repositories is not new but rapidly gaining 
momentum for a myriad of reasons. Most of these are related to the concept of 
harmonization and standardization, enabling access to interrogation of larger cohorts of 
well-preserved and synchronized specimens and data to improve returns on investment 
and increase opportunities for discovery of relevant genetic associations with disease. SA, 
which is one of 54 African countries, has a fairly well-developed infrastructure for 
scientific discovery through storage and interrogation of human biological samples. But as 
a scientific community, it is still grappling with many of the legal and ethical considerations 
necessary to lay the foundation for a rapid advancement in genomic discovery and 
applications. It is hoped that with concerted and focused attention on the need to address a 
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myriad of indigenous high burden disease entities, South Africa will enter the global 
community of genomic discovery and partner with international collaborators to fi     cost-
effective solutions to prevailing and crippling epidemics. This process is well on its way with 
the launching of the H3Africa consortium project, among others, which have kindled a 
renewed interest by national stakeholders and academic institutions to ensure that 
strategic planning, oversight mechanisms, and legislative structures are rapidly adapted 
and formalized to address biobanking needs and to prevent ambiguity in governance and 
social injustices. 
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